Atlanta Capital Management Co. L L C trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 976,278 shares of the medical research company’s stock after selling 35,151 shares during the quarter. Atlanta Capital Management Co. L L C owned approximately 0.24% of Thermo Fisher Scientific worth $184,712,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of TMO. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $108,000. Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $113,000. Ropes Wealth Advisors LLC lifted its holdings in Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares during the last quarter. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $138,000. Finally, Grove Bank & Trust lifted its holdings in Thermo Fisher Scientific by 19.9% during the 2nd quarter. Grove Bank & Trust now owns 860 shares of the medical research company’s stock worth $150,000 after purchasing an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 86.22% of the company’s stock.
In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.49% of the stock is owned by insiders.
Thermo Fisher Scientific Inc. (TMO) traded up $2.37 during midday trading on Thursday, hitting $208.66. The company’s stock had a trading volume of 1,520,725 shares, compared to its average volume of 1,549,578. Thermo Fisher Scientific Inc. has a 1 year low of $140.00 and a 1 year high of $208.72. The company has a market cap of $83,230.00, a price-to-earnings ratio of 35.43, a PEG ratio of 1.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 9.09% and a net margin of 10.44%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.03 EPS. analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.
Several analysts recently weighed in on the company. Zacks Investment Research cut Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Thursday. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. BTIG Research began coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. Leerink Swann lifted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Finally, Evercore ISI assumed coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $212.21.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/thermo-fisher-scientific-inc-tmo-shares-sold-by-atlanta-capital-management-co-l-l-c.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.